SaAWangMD

PubMed

• Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy.
  Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M Kadia, Sa A Wang
  Blood Advances. 2025-02-25
• Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
  Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi
  Leukemia. 2025-02-25
• Flow cytometric immunophenotypic features of acute myeloid leukemia with mast cell differentiation.
  Jie Xu, Do Hwan Kim, Wei Wang, Shaoying Li, Pei Lin
  American Journal of Clinical Pathology. 2025-02-12

Journal Articles

• Hematopoietic Neoplasms with 9p24/JAK2 Rearrangement: A Multicenter Study  
  Guilin Tang, Daniel A Arber, Elizabeth M Margolskee, Heesun J Rogers, Robert P Hasserjian, Eric D Hsi, Sa A Wang, Wayne Tam, Adam Bagg, Olga Weinberg, Jonathan I Lake,..., Nature
• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
• T-cell Prolymphocytic Leukemia Negative for Surface CD3 and CD45  
  Sa Wang, MD, Blood

Abstracts/Posters

• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Sa A Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Clinical, Immunophenotypic and Genomic Findings  of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018